Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS - Ziltivekimab cardiovascular outcomes in ASCVD, CKD and systemic inflammation
2020-004853-59Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD) and chronic inflammation comparing Ziltivekimab arm with Placebo arm (2 arms). Primary endpoint: Time to first occurrence of 3-point MACE. Started May 2021; status: active.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)chronic inflammation
Beyond the preview
Go deeper on 2020-004853-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004853-59.